The FDA has taken measures to simplify the path for COVID-19 screening tools and has provided information to assist organization in developing testing programs

-By KI News Team | March 18, 2021, 9:18 a.m.


The Food and Drug Administration (FDA) announced that the US government has released streamlined rules for coronavirus test developers in order to facilitate serial screening, a procedure in which the same individual is screened several times within a few days.

Testing is still a vital component of our country's battle against COVID-19. This involves screening asymptomatic individuals who could still transmit the virus in classrooms, workplaces, neighbourhoods, and other locations. Screening means putting asymptomatic people who haven't been subjected to COVID-19 to the test in order to make individual choices, such as whether or not they should be screened.

Testing is still a vital component of our country's battle against COVID-19. This involves screening asymptomatic individuals who could still transmit the virus in classrooms, workplaces, neighbourhoods, and other locations. Screening means putting asymptomatic people who haven't been subjected to COVID-19 to the test in order to make individual choices, such as whether or not they should be screened.

Serial testing entails testing the same person several times over the course of a few days, and it can help detect asymptomatic infections that may not show up in a single test. To minimise disease transmission, the Centers for Disease Control and Prevention (CDC) recommends serial testing at least once a week, as well as other prevention steps including masking and social distancing. This template is for developers of molecular and antigen tests for use in serial testing systems, as well as at-home tests for use in a serial manner outside of a testing programme, to diagnose SARS-CoV-2 infection in people who don't have any signs or other epidemiological reasons to suspect COVID-19 infection.

According to the FDA, a test that detects the virus well in symptomatic patients, when paired with serial testing, will reduce the risk of false findings in asymptomatic people.

In addition, the FDA released a fact sheet today that addresses factors to consider when choosing a test for use in a screening testing programme. The fact sheet will assist colleges, workplaces, neighbourhoods, and other organisations in choosing a screening test and understanding the distinctions between tests used for suspected COVID-19 diagnosis and those used for asymptomatic screening.